Related Experiment Video

Updated: Sep 2, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

In diabetes, some statins reduce non-HDL-C better than others vs. placebo

Michael Tanner1

  • 1NYU Grossman School of Medicine, New York, New York, USA (M.T.).

Annals of Internal Medicine
|August 1, 2022
PubMed

Insights

This study compared statins for lowering non-high density lipoprotein cholesterol in individuals with diabetes and cardiovascular risk. Atorvastatin and rosuvastatin demonstrated superior effectiveness in reducing cholesterol levels.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Diabetes and cardiovascular disease (CVD) are major global health concerns.
  • Elevated non-high density lipoprotein cholesterol (non-HDL-C) is a key risk factor for CVD.
  • Statins are widely used to manage dyslipidemia, but comparative effectiveness varies.

Purpose of the Study:

  • To compare the effectiveness of different statins in reducing non-HDL-C.
  • To evaluate statin efficacy in patients with diabetes and at high risk of CVD.
  • To inform clinical practice guidelines for lipid management.

Main Methods:

  • Systematic review and network meta-analysis.
  • Inclusion of randomized controlled trials comparing statins.
  • Focus on studies involving patients with diabetes or high CVD risk.

Main Results:

  • Atorvastatin and rosuvastatin showed greater reductions in non-HDL-C compared to other statins.
  • All analyzed statins effectively lowered non-HDL-C.
  • The magnitude of non-HDL-C reduction varied significantly between statin types.

Conclusions:

  • Atorvastatin and rosuvastatin are the most effective statins for lowering non-HDL-C in this population.
  • These findings support the use of high-intensity statins for patients with diabetes and high CVD risk.
  • Personalized statin selection may optimize cardiovascular risk reduction.
Abstract

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.2K
Cholesterol Efflux Assay07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
847
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
239
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
277
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
344
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
247